[HTML][HTML] 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American …
1. Specific recommendations for prevention strategies often depend on the ischemic
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …
stroke/transient ischemic attack subtype. Therefore, new in this guideline is a section …
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
EULAR recommendations for the management of antiphospholipid syndrome in adults
The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …
Antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …
Diagnosis and management of the antiphospholipid syndrome
D Garcia, D Erkan - New England Journal of Medicine, 2018 - Mass Medical Soc
Antiphospholipid Syndrome Antiphospholipid antibodies can induce endothelial-cell,
complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal …
complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal …
Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial
J Ordi-Ros, L Sáez-Comet… - Annals of internal …, 2019 - acpjournals.org
Background: The potential role of new oral anticoagulants in antiphospholipid antibody
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart …
The aim of this updated guideline is to provide comprehensive and timely evidence-based
recommendations on the prevention of future stroke among survivors of ischemic stroke or …
recommendations on the prevention of future stroke among survivors of ischemic stroke or …
Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials
Background The efficacy and safety of direct oral anticoagulants (DOACs) for patients with
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
JS Knight, DW Branch, TL Ortel - bmj, 2023 - bmj.com
Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …